Cargando…
Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice
BACKGROUND: Helminth infections and their components have been shown to have a protective effect on autoimmune diseases. The isolated purified protein from Schisotosoma japonicum and its potential therapeutic effect on trinitrobenzene sulfonic acid (TNBS)-induced colitis could provide an alternative...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700642/ https://www.ncbi.nlm.nih.gov/pubmed/26728323 http://dx.doi.org/10.1186/s13071-015-1288-1 |
_version_ | 1782408354486812672 |
---|---|
author | Wang, Shushu Xie, Yuanyuan Yang, Xiaodi Wang, Xuesong Yan, Ke Zhong, Zhengrong Wang, Xiaowei Xu, Yuanhong Zhang, Yi Liu, Fang Shen, Jilong |
author_facet | Wang, Shushu Xie, Yuanyuan Yang, Xiaodi Wang, Xuesong Yan, Ke Zhong, Zhengrong Wang, Xiaowei Xu, Yuanhong Zhang, Yi Liu, Fang Shen, Jilong |
author_sort | Wang, Shushu |
collection | PubMed |
description | BACKGROUND: Helminth infections and their components have been shown to have a protective effect on autoimmune diseases. The isolated purified protein from Schisotosoma japonicum and its potential therapeutic effect on trinitrobenzene sulfonic acid (TNBS)-induced colitis could provide an alternative way to treat inflammatory bowel disease (IBDs). METHODS: Colitis was induced in Balb/c mice by rectal administration of 2.5 % TNBS, followed by intraperitoneal injection of rSjcystatin 50 μg at 6 h and 24 h afterwards. The inflammation was monitored by recording weight change, stool character and bleeding, colon length, macroscopic score (MAO), microscopic score (MIO), myeloperoxidase activity (MPO) and disease activity index (DAI). The potential underlying mechanism was investigated by examining cytokine profiles including Th1 (IFNγ), Th2 (IL-4), Th17 (IL-17A) and Treg subsets from lymphocytes of spleen, mesenteric lymph nodes (MLN) and intestinal lamina propria mononuclear cells (LPMCs) by flow cytometry. The mRNA relative expressions of the cytokines in splenocytes and MLN were analysed by quantitative real time reverse-transcriptase polymerase chain reaction (qRT-PCR). Simultaneously, the concentrations of the cytokines in the colon homogenate supernatants were tested by enzyme-linked immunosorbent assay (ELISA) and key transcription factors were detected by Western blotting. RESULTS: Administration of rSjcystatin significantly reduced inflammatory parameters and ameliorated the severity of the TNBS-induced colitis through decreasing IFNγ in three organs and lifting the level of IL-4, IL-13, IL-10, and TGF-β in the colon tissues, with uptrending Tregs in the MLN and LPMC. CONCLUSION: The findings provide evidence that rSjcystatin has a therapeutic potential for diminishing colitis inflammation in Balb/c mice. The immunological mechanism may involve the down-regulation of Th1 response and up-regulation of Th2 and Tregs in the MLN and colon. |
format | Online Article Text |
id | pubmed-4700642 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47006422016-01-06 Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice Wang, Shushu Xie, Yuanyuan Yang, Xiaodi Wang, Xuesong Yan, Ke Zhong, Zhengrong Wang, Xiaowei Xu, Yuanhong Zhang, Yi Liu, Fang Shen, Jilong Parasit Vectors Research BACKGROUND: Helminth infections and their components have been shown to have a protective effect on autoimmune diseases. The isolated purified protein from Schisotosoma japonicum and its potential therapeutic effect on trinitrobenzene sulfonic acid (TNBS)-induced colitis could provide an alternative way to treat inflammatory bowel disease (IBDs). METHODS: Colitis was induced in Balb/c mice by rectal administration of 2.5 % TNBS, followed by intraperitoneal injection of rSjcystatin 50 μg at 6 h and 24 h afterwards. The inflammation was monitored by recording weight change, stool character and bleeding, colon length, macroscopic score (MAO), microscopic score (MIO), myeloperoxidase activity (MPO) and disease activity index (DAI). The potential underlying mechanism was investigated by examining cytokine profiles including Th1 (IFNγ), Th2 (IL-4), Th17 (IL-17A) and Treg subsets from lymphocytes of spleen, mesenteric lymph nodes (MLN) and intestinal lamina propria mononuclear cells (LPMCs) by flow cytometry. The mRNA relative expressions of the cytokines in splenocytes and MLN were analysed by quantitative real time reverse-transcriptase polymerase chain reaction (qRT-PCR). Simultaneously, the concentrations of the cytokines in the colon homogenate supernatants were tested by enzyme-linked immunosorbent assay (ELISA) and key transcription factors were detected by Western blotting. RESULTS: Administration of rSjcystatin significantly reduced inflammatory parameters and ameliorated the severity of the TNBS-induced colitis through decreasing IFNγ in three organs and lifting the level of IL-4, IL-13, IL-10, and TGF-β in the colon tissues, with uptrending Tregs in the MLN and LPMC. CONCLUSION: The findings provide evidence that rSjcystatin has a therapeutic potential for diminishing colitis inflammation in Balb/c mice. The immunological mechanism may involve the down-regulation of Th1 response and up-regulation of Th2 and Tregs in the MLN and colon. BioMed Central 2016-01-04 /pmc/articles/PMC4700642/ /pubmed/26728323 http://dx.doi.org/10.1186/s13071-015-1288-1 Text en © Wang et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Wang, Shushu Xie, Yuanyuan Yang, Xiaodi Wang, Xuesong Yan, Ke Zhong, Zhengrong Wang, Xiaowei Xu, Yuanhong Zhang, Yi Liu, Fang Shen, Jilong Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice |
title | Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice |
title_full | Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice |
title_fullStr | Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice |
title_full_unstemmed | Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice |
title_short | Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice |
title_sort | therapeutic potential of recombinant cystatin from schistosoma japonicum in tnbs-induced experimental colitis of mice |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700642/ https://www.ncbi.nlm.nih.gov/pubmed/26728323 http://dx.doi.org/10.1186/s13071-015-1288-1 |
work_keys_str_mv | AT wangshushu therapeuticpotentialofrecombinantcystatinfromschistosomajaponicumintnbsinducedexperimentalcolitisofmice AT xieyuanyuan therapeuticpotentialofrecombinantcystatinfromschistosomajaponicumintnbsinducedexperimentalcolitisofmice AT yangxiaodi therapeuticpotentialofrecombinantcystatinfromschistosomajaponicumintnbsinducedexperimentalcolitisofmice AT wangxuesong therapeuticpotentialofrecombinantcystatinfromschistosomajaponicumintnbsinducedexperimentalcolitisofmice AT yanke therapeuticpotentialofrecombinantcystatinfromschistosomajaponicumintnbsinducedexperimentalcolitisofmice AT zhongzhengrong therapeuticpotentialofrecombinantcystatinfromschistosomajaponicumintnbsinducedexperimentalcolitisofmice AT wangxiaowei therapeuticpotentialofrecombinantcystatinfromschistosomajaponicumintnbsinducedexperimentalcolitisofmice AT xuyuanhong therapeuticpotentialofrecombinantcystatinfromschistosomajaponicumintnbsinducedexperimentalcolitisofmice AT zhangyi therapeuticpotentialofrecombinantcystatinfromschistosomajaponicumintnbsinducedexperimentalcolitisofmice AT liufang therapeuticpotentialofrecombinantcystatinfromschistosomajaponicumintnbsinducedexperimentalcolitisofmice AT shenjilong therapeuticpotentialofrecombinantcystatinfromschistosomajaponicumintnbsinducedexperimentalcolitisofmice |